Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 454
Last updated 2026-03-19
Summary
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Conditions
Interventions
- DRUG
-
Datopotamab deruxtecan (Dato-DXd)
Intravenous (IV) Antibody drug conjugate
- DRUG
-
Administered orally
- DRUG
-
Administered as an IV
- DRUG
-
Volrustomig
Administered as an IV
- DRUG
-
Administered as an IV
- DRUG
-
Administered as an IV
- DRUG
-
Administered as an IV
- DRUG
-
Prednisone/ prednisolone
Administered orally
- DRUG
-
Administered as an IV
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Global Clinical Lead, MD · AstraZeneca
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 130 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-06
- Primary Completion
- 2027-10-01
- Completion
- 2027-10-01
- FDA Drug
- Yes
Countries
- United States
- Canada
- China
- France
- Germany
- Italy
- Japan
- Poland
- South Korea
- Spain
- Switzerland
- Taiwan
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
NCT03772561 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
NCT06293651 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
NCT04857138 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study in Patients With Solid Tumours
NCT00496028 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT05765851 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
NCT00243347 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
NCT02807636 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
NCT04999969 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
NCT02649790 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
NCT00732420 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
NCT00516802 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Intravenous RXDX-107 in Patients With Solid Tumors
NCT02548390 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531 ·Status: COMPLETED ·Phase: PHASE1
-
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00004151 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
NCT02617277 ·Status: COMPLETED ·Phase: PHASE1
-
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
NCT00454649 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
NCT00475956 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145 ·Status: RECRUITING ·Phase: PHASE1/PHASE2